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Overt hypoadrenalism is uncommon in patients with stage 3 
and 4 bronchogenic carcinoma 
Ian L Ross, Suzaan Marais, Peter Raubenheimer, Raymond Abratt, Sedick Isaacs, Steven Soule 
Introduction. Lung cancer is the leading cause of cancer 
mortality in most countries. The adrenal glands are common 
sites of metastatic lung cancer as approximately 40% of 
subjects with stage 4 bronchogenic carcinoma have adrenal 
metastases. The prevalence of biochemical hypoadrenalism is, 
however, remarkably poorly documented. 
Objectives. Our study aimed to determine the prevalence of 
primary hypoadrenalism, as defined by a subnormal cortisol 
response to the 250 J.lg adrenocorticotrophic hormone (ACTH) 
stimulation test, in patients with stage 3 and 4 lung cancer. 
Methods. Thirty patients with stage 3 and 4 bronchogenic 
carcinoma were prospectively recruited from the bronchus 
clinic. Demographic data and electrolytes Were recorded and 
each patient had a 250 J.lg ACTH stimulation test to determine 
the prevalence of overt adrenal insufficiency, defined as a +30 
minute cortisol of less than 550 nmol/1. 
Results. The median age and quartile deviation was 62 (10) 
years and the median basal cortisol was 429.5 (321) nmol/l. 
Departments of Endocrinology, Radiation Oncology and Medical Informatics, 
Groote Schuur Hospital, Cape Town 
Ian L Ross, MB ChB, FCP (SA), Cert Endocrinol & Metab (SA) 
Suz~an Marais, MB ChB 
Peter Raubenheimer, MB ChB, FCP (SA) 
Raymond Abratt, MB ChB, FFRadT, MMed 
Sedick Isaacs, MSc, PhD 
Steven Soule, MB ChB, DCH, FCP (SA) (Current address: Endocrinology 
Department, Christchurch Hospital, Private Bag 4710, Christchurch, New 
Zealand) 
September 2003, Vol. 93, No. 9 SAMJ 
The median peak cortisol was 828.5 (342) nmol/1 (range 
536- 1 675 nmol/1). Twenty-eight patients (93.3%) had an 
appropriate rise of cortisol to greater than 550 nmol/1 
following 250 j.lg ACTH stimulation. Two patients (6.7%) had 
mild primary adrenal failure with a peak cortisol between 500 
and 550 nmol/1 associated with a raised plasma ACTH 
concentration (131.4 and 10.5 pmol/1, normal2.2 -10 pmol/1). 
Twenty-eight patients (92.9%) were normonatraemic, while 
the two hyponatraemic patients had biochemical evidence of 
the syndrome of inappropriate antidiuretic hormone 
secretion. 
Conclusion. In conclusion, despite evidence that the adrenal 
glands of patients with disseminated bronchogenic carcinoma 
are frequently affected by metastatic disease, biochemical 
evidence of clinically significant hypoadrenalism is relatively 
uncommon and is not accurately predicted by electrolyte 
abnormalities. 
S Afr Med 1 2003; 93: 695-699. 
Lung cancer is the leading cause of cancer mortality in most 
countries, with the global incidence increasing by 0.5% per 
year.1 The adrenal glands are common sites of metastases, as 
evidenced by a series of 500 consecutive cancer necropsies, 
where 42% of metastatic lung cancers involved the adrenal 
glands. This high prevalence of adrenal metastases may reflect 
the rich sinusoidal blood supply and high local concentration 
of glucocorticoids, which may promote implantation of 
metastases.' 
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Despite the plethora of reports confirming the high 
frequency of adrenal metastases in patients with bronchogenic 
carcinoma, the prevalence of hypoadrenalism is remarkably 
poorly documented. One may speculate that hypoadrenalism 
may be uncommon as the adrenal glands possess large 
functional reserve, since 90% of both adrenal cortices must be 
replaced by tumour before adrenocortical insufficiency 
develops.'·' There are, however, several factors that may 
potentially account for underreporting of hypoadrenalism 
associated with metastatic carcinoma. Firstly, since the 
symptoms of adrenal insufficiency are similar to those of 
extensive metastatic disease, adrenal insufficiency is seldom 
considered in a patient whose condition is progressively 
deteriorating with increasing anorexia, malaise and weight 
loss! Secondly, the treatment of metastatic cancer of the lung 
with corticosteroids may mask the state of adrenal 
insufficiency? Finally, since the syndrome of inappropriate 
antidiuretic hormone (SIADH) is often encountered in small-
cell carcinoma, hyponatraemia may be incorrectly attributed to 
SIADH rather than primary adrenal insufficiency.' 
In 1855 Addison8 first suggested that adrenal metastases 
could induce adrenal insufficiency. Several isolated cases 
supporting this contention have subsequently been reported.9•10 
.In addition, there have been reports of adrenal insufficiency as 
the sole manifestation of cancer and of malignancies initially 
presenting as an Addisonian crisisY-12 There are only two 
prospective studies examining the prevalence of 
hypoadrenalism in metastatic bronchogenic carcinoma. 
Redman and colleagues13 reported a 33% prevalence of 
hypoadrenalism in an early study of 15 patients with a variety 
of metastatic carcinomas and bilateral adrenal enlargement on 
CT scan. However, the criteria for hypoadrenalism used in this 
paper (cortisol increment < 150 nmol/1 or a peak cortisol 
concentration < 415 nmol/l) do not accord with validated 
criteria for primary adrenal insufficiency.14•15 Lutz and 
colleagues16 employed more conventional diagnostic criteria 
and studied patients with either unilateral (N == 8) or bilateral 
(N == 9) adrenal metastases. In this group selected for the 
presence of adrenal metastases there was no evidence of overt 
hypoadrenalism. We were interested to determine the 
prevalence of primary hypoadrenalism prospectively in 
patients with advanced bronchogenic carcinoma not pre-
selected for the presence of adrenal metastases. We therefore 
designed a prospective stl1dy of patients with advanced 
bronchogenic carcinoma with the following objective, namely 
to determine the prevalence of primary hypoadrenalism in 
patients with stage 3 and 4 lung cancer, using validated 
criteria. 
Materials and methods 
Thirty patients were recruited prospectively from the combined 
bronchus clinic at Groote Schuur Hospital, Cape Town. 
Patients were considered eligible for the study if they had 
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histological or cytological proof of primary lung carcinoma 
with stage 3 or 4 (non-small-cell carcinoma) or advanced 
disease (small-cell carcinoma) according to the 1997 
international TNM (tumour, node, metastasis) staging system 
for lung cancer.17 Patients were considered to have metastatic 
disease if one or more of the following conditions were met: 
pathological fractures or radiological bony erosions, ultrasound 
or CT evidence of hepatic metastases, contralateral lung 
involvement, cutaneous involvement proved by biopsy, CT 
evidence of brain metastases or extension into pleura, 
pericardium, diaphragm or mediastinal nodes. Patients were 
excluded if they had had oral glucocorticoid treatment within 
the previous 6 months or if the subjects were on therapy that 
could influence cortisol metabolism, e.g. rifampicin. All 
patients provided written informed consent and the study was 
approved by the Research Ethics Committee of the University 
of Cape Town Medical School. 
The nature of metastatic disease, height, weight and body 
mass index were recorded. Hyperpigmentation and postural 
hypotension were noted (a fall in systolic blood pressure > 20 
mmHg and I or a- fall in diastolic blood pressure > 1 0 mmHg 
after standing for 3 minutes) and serum, urinary electrolytes 
and osmolality were measured. SIADH was suggested by the 
combination of hyponatraemia (Na+ < 130 mmol/1) with low 
plasma osmolality(< 280 mOsm/kg), inappropriately high 
urine osmolality and urinary sodium > 20 mmol/1, in the 
absence of clinical volume depletion or biochemical evidence of 
hypothyroidism, hypoadrenalism or renal impairment. A 
standard intravenous 250 pg adrenocorticotrophic hormone 
(ACTH) test (tetracosactide) was performed and patients were 
defined as having overt primary hypoadrenalism if the 30-
minute cortisol was < 550 nmol/1 with increased basal plasma 
ACTH (normal2.2- 10 pmol/1).18 Compensated 
hypoadrenalism was defined as a ratio of ACTH/ cortisol 
(pmol/l:nmol/1) > 0.028.19 Cortisol was measured using the 
Automated Chemiluminescence System, Cheiron ACS 180 
(Beyer Corporation, New York 10591-509). The inter- and intra-
assay coefficient of variation was 6.4- 9.7%. ACTH assay was 
performed using the Immulite 2000 chemiluminescent 
immunoassay system and the inter- and intra-assay of 
coefficient of variation was 6.3 - 8%. Results are expressed as 
medians and quartile deviation (QD). Since sarriple sizes were 
small and variances were generally not homogeneous the 
Mann-Whitney test was employed for all the comparisons. 
Results 
Baseline demographic data 
Baseline demographic data are summarised in Table I. The 
mean± standard deviation (SD) age was 60.9 ± 9.45 years. 
Seven patients had proven advanced small-cell carcinoma, 
whereas 23 patients had non-small-cell carcinoma, of whom 14 
had stage 3 (61 %) and 9 stage 4 disease (39%). 
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The basal cortisol ranged from 129 to 978 nmol/1 in both 
groups combined, while the median basal cortisol was 432 
nmol/1 (QD 473) for the non-small-cell carcinoma group and 
212 nmol/1 (QD 505) for the small-cell carcinoma group 
(p > 0.05). The median basal ACTH was 2.8 pmol/1 (QD 2.2) for 
the non-small-cell carcinoma group and 6.35 pmol/1 (QD 9.75) 
for the small-cell group (p > 0.05). Four patients (13.3%) had an 
abnormally elevated plasma ACTH concentration. 
Cortisol response to 250 pg ACTH stimulation 
(Fig. 1) 
The overall median peak serum cortisol 30 minutes after 
250 p.g ACTH stimulation was 828.5 nmol/1 (QD 345), range 
536 - 1 675 nmol/1. When comparing the two histological 
subgroups, the median peak serum cortisol was 832 nmol/1 
(QD 336) for the non-small-cell carcinoma group and 792 
nmol/1 (QD 563) for the small-cell carcinoma group (p = 0.86). 
There was a close correlation between basal and 30-minute 
cortisol (r = 0.78, p < 0.0005), while the correlation between 
basal and incremental cortisol was poor (r = -0.07, p = 0.9). 
Twenty-eight patients (93.3%) had an appropriate rise of 
cortisol to greater than 550 nmol/1 following 250 ].lg ACTH 
stimulation. Two patients (6.7%) had definite evidence of 
adrenal insufficiency, with a peak cortisol of 536 and 545 
nmol/1 associated with a raised plasma ACTH concentration of 
131.4 and 10.5 pmol/1 respectively (normal2.2- 10 pmol/1). 
The overall prevalence of adrenal insufficiency was therefore 
6.7% in our series (95% confidence interval (CI): 0.8%- 22.1 %). 
Two further subjects had an elevated basal ACTH 
concentration of 58.9 and 13.4 pmol/1 (normal 2.2- 10 pmol/1) 
and their peak cortisol levels following ACTH stimulation were 
997 and 762 nmol/1 respectively. In order to ascertain whether 
these two subjects had compensated hypoadrenalism we 
determined the ACTH-to-cortisol ratio, which was 0.059 and 
0.017 respectively (ratio > 0.028 suggests compensated 
hypoadrenalism).16 Thus we found an additional patient who 
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Fig. 1. Basal and 30-minute plasma cortisol concentrations following 
250 ttg ACTH stimulation. The horizontal line at 550 nmol/l 
indicates the minimum cortisol value that defines a normal +30 
minute response to ACTH stimulation. 
had compensated hypoadrenalism (ACTH-to-cortisol ratio 
0.059), bringing the overall prevalence of hypoadrenalism in 
our study to IO%. 
Clinical and biochemical predictors of 
hypoadrenalism 
Clinical evidence of hyperpigmentation was not predictive of 
hypoadrenalism since none of the 23.3% of the patients with 
hyperpigmentation had a subnormal serum cortisol response to 
ACTH stimulation. Similarly, postural hypotension was of 
limited utility since 13.3% of patients had postural hypotension 
and only 1 of these subjects had compensated hypoadrenalism. 
Twenty-eight patients (93.3%), including the 2 with adrenal 
insufficiency, were normonatraemic, while the 2 hyponatraemic 
patients (6.7%) had biochemical evidence of SIADH. All miJ 
patients were normokalaemic and the 2 patients with 
hypercalcaemia (6.7%) had normal adrenal function, suggesting 
that the hypercalcaemia was related to the underlying 
malignancy rather than to cortisol deficiency. Despite 
convincing evidence in the literature that a basal 08h00 cortisol 
of less than 100 nmol/1 reliably predicts hypoadrenalism, this 
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cutoff was of limited clinical utility in our study where the 
subjects with both mild and compensated adrenal failure had 
basal cortisol levels ranging from 129 nmol/1 to 815 nmol/!.14 
Discussion 
Despite the fact that the adrenal glands are common sites of 
metastatic spread in patients with bronchogenic carcinoma, our 
study suggests that clinically relevant hypoadrenalism is 
distinctly uncommon. However, 2 patients had adrenal 
insufficiency, with a peak cortisol of between 500 and 550 
nmol/1 was associated with a raised plasma ACTH 
concentration. It is relevant to note that these patients had no . 
associated clinical or biochemical features of hypoadrenalism 
· and were not considered to warrant glucorticoid 
supplementation. In addition 2 further patients with an 
elevated basal plasma ACTH of 58.9 and 13.9 pmol/1 
responded to stimulation with 250 rg ACTH, with a normal 
cortisol response of 997 and 762 nmol/l. These patients may be 
considered to have compensated primary adrenal insufficiency 
and although they would be at increased risk of developing 
overt primary adrenal insufficiency in the future, there would 
currently be no benefit in glucocorticoid supplementation. 
The 250 rg dose of ACTH used in this study results in 
markedly supraphysiological concentrations of ACTH, which 
could potentially limit the ability of the test to detect subtle 
degrees of cortisol deficiency (false-negative test). The low-
dose 1 ].lg ACTH stimulation test has therefore recently been 
advocated as a more sensitive test for hypoadrenalism, 
particularly in the setting of suspected ACTH deficiency. Early 
enthusiasm for the sensitivity of the 1 ].lg ACTH stimulation 
test in the evaluation of patients with pituitary disease has, 
however, been dampened by several reports indicating that in 
the setting of partial ACTH deficiency, the low-dose test may, 
like the standard 250 rg test, produce false-negative results.20 
In the single report exploring the utility of the 1 ].lg ACTH 
stimulation test for the diagnosis of primary hypoadrenalism in 
patients with pre-clinical hypoadrenalism and positive adrenal 
antibodies there was full concordance between the results of 
the 250].1g and 1 ].lg tests, indicating no diagnostic advantage 
for the low-dose test.'1 This limited sensitivity probably relates 
to the attainment of supr<lphysiological concentrations of 
ACTH following administration of both the 250 ].lg (60 000 
ng/1) and 1 ].lg (> 100 ng/1) ACTH doses, concentrations which 
are substantially higher than the plasma ACTH concentration 
that elicits a maximal cortisol response (70 - SO ng /1).22 In light 
miJ of these data we decided to use the conventional 250 ].lg ACTH 
stimulation test for the evaluation of hypoadrenqlism in our 
patient cohort. A crucial characteristic of our patient cohort 
was that none of our patients was acutely unwell at the time of 
being evaluated. 
The relatively low prevalence of hypoadrenalism reported in 
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this study contrasts sharply with previous studies reporting 
that more than 40% of patients with metastatic bronchogenic 
carcinoma have adrenal metastases at necropsy.23 This 
discrepancy between frequent pathological adrenal 
involvement and infrequent biochemical hypoadrenalism is 
well doc1,1mented and attests to the remarkable functional 
reserve of the adrenal glands."' In light of our findings it is 
important to evaluate earlier studies of hypoadrenalism in 
patients with metastatic bronchogenic carcinoma critically. In a 
study of only 15 patients with metastatic carcinoma and 
bilateral adrenal enlargement on CT scan Redman and 
colleagues13 reported a 33% prevalence of hypoadrenalism. 
However, the criteria used to define hypoadrenalism in this 
study, namely failure to increase serum cortisol by at least 
150 nmol/l and/or a peak cortisol of less than 415 nmol/1 
following 250 ].lg ACTH stimulation, are arbitrary and do not 
accord with any accepted diagnostic criteria for 
' hypoadrenalism.14•15 Consensus is now emerging that 
calculation of the increment in serum cortisol is of limited 
value in the assessment of the adrenocortical function, as a 
maximally stressed patient with an intact adrenal axis may 
have a blunted cortisol response to exogenous ACTH." If one 
re-examines the study by Redman et al." employing validated 
criteria, namely a peak cortisol response to ACTH of less than 
550 nmol/1, then the prevalence of hypoadrenalism is reduced 
to 20%. A recent study by Lutz and colleagues16 examined 
adrenocortical function in patients with either unilateral 
(N = 8) or bilateral (N = 9) macrometastases of the adrenal 
gland. Interestingly, no patient had overt adrenal insufficiency 
(defined as a serum cortisol response to ACTH stimulation 
below 560 nmol/1, while only 2 of 9 patients (22%) with 
bilateral macrometastases had subclinical hypoadrenalism 
(defined as an elevated basal ACTH/cortisol ratio).~' The 
reported prevalence of overt hypoadrenalism of 20-22% from 
studies that selected patients for the presence of adrenal 
metastases is in accordance with our study, which documented 
a combined prevalence of hypoadrenalism (overt and 
compensated) of 10% in a group of patients with advanced 
bronchogenic carcinoma who were not selected for CT 
evidence of adrenal metastases. 
The predictive value of clinical and biochemical markers of 
hypoadrenalism in our study was poor since none of the 
patients considered to have hyperpigmentation had 
biochemical hypoadrenalism. Conversely, the 2 patients with 
mild adrenal insufficiency and elevated plasma ACTH 
concentration were not hyperpigmented. We propose that 
hyperpigmentation reflects longstanding ACTH excess which 
is not typically a feature in patients with adrenal metastases. 
Similarly, there was no correlation between postural 
hypotension and hypoadrenalism. Although hyponatraemia 
and hyperkalaemia had a prevalence of 78% and 52% 
respectively in our previous series of 50 patients with 
Addison's disease, neither of the 2 patients with mild 
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hypoadrenalism in this study had any electrolyte disturbance.25 
This likely reflects the mild cortisol deficiency with 
preservation of mineralocorticoid function in this group of 
patients. Finally, basal cortisol cannot be used as a predictor 
for overt or compensated hypoadrenalism. 
There are several potential criticisms of our study. Firstly the 
limited number of enrolled subjects may have resulted in a 
falsely low prevalence of hypoadrenalism. This uncertainty is 
reflected in the wide Cis for the prevalence of overt 
hypoadrenalism of 0.8-22.1% and can only be addressed by 
increasing the number of patients recruited in future studies. In 
addition, although the patients had advanced bronchogenic 
carcinoma according to conventional staging, serum albumin 
and body mass index were remarkably well preserved (Table I). It 
is therefore possible that patients with clinically more 
advanced bronchogenic carcinoma would have a higher 
prevalence of primary hypoadrenalism. Finally, patients were 
not selected for the presence of adrenal metastases on CT 
imaging as in previous studies. We were, however, interested 
in answering a clinically relevant question, namely the 
prevalence of hypoadrenalism in unselected patients with 
advanced bronchogenic carcinoma as this is the problem 
frequently faced by clinicians, who typically do not have CT 
data available when assessing a patient with advanced 
malignancy and possible hypoadrenalism. It would, however, 
have been interesting to verify the presence of adrenal 
metastases in our small group of patients with overt and 
compensated adrenal failure. 
In conclusion, despite frequent pathological adrenal 
involvement in patients with metastatic bronchogenic 
carcinoma, clinically relevant hypoadrenalism is distinctly 
uncommon. Furthermore, electrolyte disturbances and basal 
cortisol concentration are of limited use in identifying the 
occasional patient with mild hypoadrenalism. 
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